Singh Amandeep, Garg Rajat, Lopez Rocio, Alkhouri Naim
Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e624-e626. doi: 10.1016/j.cgh.2021.01.010. Epub 2021 Jan 9.
Type 2 diabetes (T2D) is a risk for advanced fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). Recent data suggest that commonly used fibrosis scores (NAFLD fibrosis score [NFS], aspartate to alanine aminotransferase ratio [AST/ALT], AST to platelet ratio index, and Fibrosis-4) may have low sensitivity and negative predictive value to detect AF in patients with diabetes. The aim of this study was to develop a simple noninvasive fibrosis score to detect AF in patients with diabetes and compare its performance with other fibrosis scores.
2型糖尿病(T2D)是非酒精性脂肪性肝病(NAFLD)患者发生晚期肝纤维化(AF)的一个风险因素。最近的数据表明,常用的肝纤维化评分(非酒精性脂肪性肝病纤维化评分[NFS]、天冬氨酸与丙氨酸转氨酶比值[AST/ALT]、AST与血小板比值指数以及Fibrosis-4)在检测糖尿病患者的AF时可能具有较低的敏感性和阴性预测值。本研究的目的是开发一种简单的非侵入性肝纤维化评分,以检测糖尿病患者的AF,并将其性能与其他肝纤维化评分进行比较。